<?xml version="1.0" encoding="UTF-8"?>
<ref id="B16-pharmaceuticals-13-00455">
 <label>16.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Konmun</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Danwilai</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Ngamphaiboon</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Sripanidkulchai</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Sookprasert</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Subongkot</surname>
    <given-names>S.</given-names>
   </name>
  </person-group>
  <article-title>A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy</article-title>
  <source>Med. Oncol.</source>
  <year>2017</year>
  <volume>34</volume>
  <fpage>69</fpage>
  <pub-id pub-id-type="doi">10.1007/s12032-017-0931-4</pub-id>
  <pub-id pub-id-type="pmid">28349496</pub-id>
 </element-citation>
</ref>
